PTJ
OCUL icon

Paul Tudor Jones’s Ocular Therapeutix OCUL Stock Holding History

Paul Tudor Jones’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Sell
171,400
-343,700
-67% -$3.12M ﹤0.01% 2064
2026
Q1 		$4.36M Buy
515,100
+218,500
+74% +$2.08M 0.01% 1251
2025
Q4 		$3.6M Buy
+296,600
New +$3.6M 0.01% 1372

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's OCUL Position: Q2 2026 in Review

Paul Tudor Jones reduced its Ocular Therapeutix (OCUL) stake by 15% in Q2 2026, selling an estimated $831K and leaving 522,663 shares worth $5.13M. The position accounts for 0.01% of the portfolio, ranked #1262.

Paul Tudor Jones first reported a position in OCUL in Q2 2015 and has held it in 17 quarters since. The position peaked at $6.01M in Q4 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Paul Tudor Jones held 522,663 shares of Ocular Therapeutix worth $5.13M as of Q2 2026.
  • Paul Tudor Jones sold 91,715 Ocular Therapeutix shares in Q2 2026, an estimated $831K.
  • Ocular Therapeutix made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1262 holding.
  • Paul Tudor Jones first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 17 quarters since.
  • Paul Tudor Jones's Ocular Therapeutix position peaked at $6.01M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.